While the conventional therapeutic applications of GLP-1RAs have primarily focused on metabolic disorders, their multifaceted neuroprotective properties and anti-inflammatory mechanisms present a distinctive therapeutic opportunity for ophthalmic pathologies, potentially offering direct ocular benefits beyond systemic metabolic control
These changes will affect fully insured large group commercial members, with a significant shift coming on January 1, 2025, when coverage for these medications will be discontinued altogether
Ghrelin levels rise before meals, peak when you are hungry, and fall after eating
An increased risk of thyroid C-cell tumors is noted on the FDA boxed warning
What results can be expected
Strinic D, Petrovic A, Balenovic D, et al